A Phase 1 interventional study of Baricitinib suspension and Baricitinib tablet in Healthy, sponsored by Eli Lilly and Company. Completed at 1 site in Singapore. Open to participants aged 21 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-03-26.
Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purposes of this study are to determine:
The study has two parts. Individuals will participate in only one part.
Participants will be admitted to the clinical research unit (CRU) and will be discharged from the CRU following the completion of 3 overnight stays.
Each part of this study will last from 8-10 days, not including screening. Follow-up will occur 7 to 14 days after the last dose of baricitinib.
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
4 mg (milligram) baricitinib suspension test formulation (TF) administered orally (PO) without water following a 10 hour fast. (Baricitinib T1)
Drug: Baricitinib suspension
4 mg baricitinib suspension formulation (TF) administered PO prior to 240 mL water following a 10 hour fast (Baricitinib T2)
Drug: Baricitinib suspension
4 mg baricitinib tablet administered PO, taken with 240 mL water following a 10 hour fast (baricitinib R)
Drug: Baricitinib tablet
4 mg baricitinib suspension test formulation (TF) administered after 10 hour fast. (TF fasting)
Drug: Baricitinib suspension
4 mg baricitinib suspension TF administered after a high fat meal.(baricitinib TF Fed)
Drug: Baricitinib suspension
Administered orally
Also known as: LY3009104
Administered orally
Also known as: LY3009104
Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of Baricitinib Following a Single Oral Dose
PK: Cmax of baricitinib after a single oral dose
Time frame: Predose, 0.25 hour (hr), 0.5 hr, 0.75 hr, 1 hr, 1.5 hr, 2 hr, 3 hr, 4 hr, 6 hr, 9 hr, 12 hr, 24 hr, 36 hr, 48 hr postdose
PK: Area Under the Concentration Versus Time Curve From Time Zero to the Last Time Point With a Measurable Concentration (AUC[0-tlast]) of Baricitinib Following a Single Oral Dose
PK: AUC(0-tlast) of Baricitinib, measured in hour times nanogram per milliliter (ng\*hr/mL)
Time frame: Predose, 0.25 hour (hr), 0.5 hr, 0.75 hr, 1 hr, 1.5 hr, 2 hr, 3 hr, 4 hr, 6 hr, 9 hr, 12 hr, 24 hr, 36 hr, 48 hr postdose
PK: Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC[0-∞]) of Baricitinib Following a Single Oral Dose
PK: AUC(0-∞) of Baricitinib
Time frame: Predose, 0.25 hour (hr), 0.5 hr, 0.75 hr, 1 hr, 1.5 hr, 2 hr, 3 hr, 4 hr, 6 hr, 9 hr, 12 hr, 24 hr, 36 hr, 48 hr postdose
| Milestone | Part A: Sequence ABC | Part A: Sequence BCA | Part A: Sequence CAB | Part B: Sequence DE | Part B:Sequence ED |
|---|---|---|---|---|---|
| Started | 8 | 8 | 8 | 0 | 0 |
| Received at least 1 dose of study drug | 8 | 8 | 8 | 0 | 0 |
| Completed | 8 | 8 | 8 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 |
| Milestone | Part A: Sequence ABC | Part A: Sequence BCA | Part A: Sequence CAB | Part B: Sequence DE | Part B:Sequence ED |
|---|---|---|---|---|---|
| Started | 8 | 8 | 8 | 0 | 0 |
| Received at least 1 dose of study drug | 8 | 8 | 8 | 0 | 0 |
| Completed | 8 | 8 | 8 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 |
| Milestone | Part A: Sequence ABC | Part A: Sequence BCA | Part A: Sequence CAB | Part B: Sequence DE | Part B:Sequence ED |
|---|---|---|---|---|---|
| Started | 8 | 8 | 8 | 0 | 0 |
| Received at least 1 dose of study drug | 8 | 8 | 8 | 0 | 0 |
| Completed | 8 | 8 | 8 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 |
| Milestone | Part A: Sequence ABC | Part A: Sequence BCA | Part A: Sequence CAB | Part B: Sequence DE | Part B:Sequence ED |
|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 9 | 9 |
| Received at least 1 dose of study drug | 0 | 0 | 0 | 9 | 9 |
| Completed | 0 | 0 | 0 | 9 | 9 |
| Not completed | 0 | 0 | 0 | 0 | 0 |
| Milestone | Part A: Sequence ABC | Part A: Sequence BCA | Part A: Sequence CAB | Part B: Sequence DE | Part B:Sequence ED |
|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 9 | 9 |
| Received at least 1 dose of study drug | 0 | 0 | 0 | 9 | 9 |
| Completed | 0 | 0 | 0 | 9 | 9 |
| Not completed | 0 | 0 | 0 | 0 | 0 |
PK: Cmax of baricitinib after a single oral dose
| nanograms per milliliter (ng/mL) | Part A: Baricitinib T1 | Part A: Baricitinib T2 | Part A: Baricitinib R | Part B: Baricitinib TF Fasted | Part B: Baricitinib TF Fed |
|---|---|---|---|---|---|
| Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of Baricitinib Following a Single Oral Dose | 49.8 ± 21 | 49.6 ± 24 | 47.8 ± 25 | 47.9 ± 22 | 32.5 ± 22 |
PK: AUC(0-tlast) of Baricitinib, measured in hour times nanogram per milliliter (ng\*hr/mL)
| ng*hr/mL | Part A: Baricitinib T1 | Part A: Baricitinib T2 | Part A: Baricitinib R | Part B: Baricitinib TF Fasted | Part B: Baricitinib TF Fed |
|---|---|---|---|---|---|
| PK: Area Under the Concentration Versus Time Curve From Time Zero to the Last Time Point With a Measurable Concentration (AUC[0-tlast]) of Baricitinib Following a Single Oral Dose | 314 ± 19 | 315 ± 17 | 216 ± 18 | 281 ± 22 | 273 ± 20 |
PK: AUC(0-∞) of Baricitinib
| ng*hr/mL | Part A: Baricitinib T1 | Part A: Baricitinib T2 | Part A: Baricitinib R | Part B: Baricitinib TF Fasted | Part B: Baricitinib TF Fed |
|---|---|---|---|---|---|
| PK: Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC[0-∞]) of Baricitinib Following a Single Oral Dose | 319 ± 19 | 319 ± 17 | 319 ± 17 | 284 ± 22 | 282 ± 21 |
Collected over Baseline through end of study (Up to 120 days). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part A: Baricitinib T1 | 0/24 (0%) | 0/24 (0%) | 2/24 (8.3%) |
| Part A: Baricitinib T2 | 0/24 (0%) | 0/24 (0%) | 1/24 (4.2%) |
| Part A: Baricitinib R | 0/24 (0%) | 0/24 (0%) | 4/24 (16.7%) |
| Part B: Baricitinib TF Fasted | 0/18 (0%) | 0/18 (0%) | 1/18 (5.6%) |
| Part B: Baricitinib TF Fed | 0/18 (0%) | 0/18 (0%) | 5/18 (27.8%) |
| Event | Part A: Baricitinib T1 | Part A: Baricitinib T2 | Part A: Baricitinib R | Part B: Baricitinib TF Fasted | Part B: Baricitinib TF Fed |
|---|---|---|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 0/24 | 0/24 | 0/24 | 0/18 | 4/18 |
| Catheter site painGeneral disorders | 2/24 | 0/24 | 0/24 | 0/18 | 1/18 |
| Catheter site swellingGeneral disorders | 2/24 | 1/24 | 1/24 | 0/18 | 1/18 |
| Musculoskeletal painMusculoskeletal and connective tissue disorders | 0/24 | 0/24 | 2/24 | 0/18 | 0/18 |
| Catheter site bruiseGeneral disorders | 0/24 | 0/24 | 1/24 | 0/18 | 1/18 |
| PainGeneral disorders | 0/24 | 0/24 | 0/24 | 0/18 | 1/18 |
| PyrexiaGeneral disorders | 0/24 | 0/24 | 0/24 | 0/18 | 1/18 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 0/24 | 0/24 | 0/24 | 1/18 | 0/18 |
All participants in Part A or Part B that received at least 1 dose of study drug.
| Age, Continuous(years) | Part A:All Participants | Part B: All Participants | Total |
|---|---|---|---|
| Mean | 39.9 ± 8.5 | 41.1 ± 11.3 | 40.4 ± 9.7 |
| Sex: Female, Male(Participants) | Part A:All Participants | Part B: All Participants | Total |
|---|---|---|---|
| Female | 1 | 0 | 1 |
| Male | 23 | 18 | 41 |
| Ethnicity (NIH/OMB)(Participants) | Part A:All Participants | Part B: All Participants | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 24 | 18 | 42 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Part A:All Participants | Part B: All Participants | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 24 | 17 | 41 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 0 | 0 | 0 |
| More than one race | 0 | 1 | 1 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Part A:All Participants | Part B: All Participants | Total |
|---|---|---|---|
| Singapore | 24 | 18 | 42 |
| Body Mass Index (BMI)(kilograms per meter squared (kg/m^2)) | Part A:All Participants | Part B: All Participants | Total |
|---|---|---|---|
| Mean | 24.14 ± 2.55 | 25.36 ± 3.03 | 24.5 ± 2.8 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jun 2017 to primary completion in Jul 2017, 1 month.
Results were first posted in Mar 2019, 1 year 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Baricitinib